CVS rejected coverage of Gilead's new HIV prevention drug Yeztugo, citing regulatory and financial factors, while facing nearly $290 million in Medicare overcharge penalties.

Kite has entered into a definitive agreement to acquire Interius BioTherapeutics, a privately held company developing in vivo CAR therapeutics.

CVS Health (CVS) won't include Gilead's (GILD) new HIV drug Yeztugo in its commercial healthcare plans, due to clinical, ...

Investing.com -- Gilead Sciences (NASDAQ:GILD) stock fell 2.7% in pre-market trading Thursday after reports that CVS Health (NYSE:CVS) will not add the company’s new HIV prevention drug, Yeztugo, to ...

Gilead Sciences is accelerating its growth rate and Yeztugo might be another major blockbuster. GILD stock is still trading ...

Trudi Suzette Harman, 70, of Mt. Gilead, OH, went to be with the Lord on Monday, August 18, 2025, at her residence. She was born on November 29, 1954, to David Thompson and Shirley (Brust) Bixler in ...

By Deena Beasley (Reuters) -CVS Health, which runs the largest U.S. pharmacy benefit manager, will not add Gilead Sciences' ...

"The Handmaid's Tale" star O-T Fagbenle reacts to Elisabeth Moss' Emmy snub for show's sixth and final season.

Investing.com -- CVS Health (NYSE: CVS) will not include Gilead Sciences (NASDAQ: GILD )’ new HIV prevention drug Yeztugo in its commercial plans for the time being, despite the medication’s proven ...

As the 2025-2026 school year kicks off, Mount Gilead EV Schools is excited to invite students, families, and community ...

Do you know a former student-athlete, coach, or contributor who made a lasting impact on Mount Gilead High School athletics?